Skip to content

Replimune Group REPL Other Income (Expense)

Other Income (Expense) at other companies

Amgen logo
AmgenAMGN
$75M-95.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$188.3M-39.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$2.51M-513%
CG Oncology logo
CG OncologyCGON
$6.19M-20.2%
Erasca, Inc. logo
Erasca, Inc.ERAS
$4.47M-4.1%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$5.3M-32.1%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's other income (expense)?
Replimune Group (REPL) reported other income (expense) of $627K in Q4 2025.
How has Replimune Group's other income (expense) changed year-over-year?
Replimune Group's other income (expense) increased by 146.9% year-over-year, from $254K to $627K.
What is the long-term trend for Replimune Group's other income (expense)?
Over 3 years (2022 to 2025), Replimune Group's other income (expense) has grown at a 276.2% compound annual growth rate (CAGR), from $278K to $14.8M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.